Skip to main content

Table 1 The apoptosis and cell cycle distributon of OVCAR3 cells after the sequential combination treatment of AdHTVP2G5-rev-casp3(MOI = 10)for 36 hrs or 72 hrs followed by flavopiridol (300 nM) for 48 hrs

From: Sequential combination therapy with flavopiridol and autocatalytic caspase-3 driven by amplified hTERT promoter synergistically suppresses human ovarian carcinoma growth in vitro and in mice

  Cell apoptosis rate (%) Cell cycle distribution(%)
G1 S G2/M
Negative control 1.1 ± 2.9 51.7 ± 3.4 29.4 ± 5.2 18.9 ± 1.9
Flavopiridol(300nM) 24 hs 10.0 ± 3.2 63.8 ± 3.9 14.3 ± 1.5 21.9 ± 2.6
Ad. 36 hs 2.1 ± 0.3 52.6 ± 4.8 20.3 ± 2.7 27.1 ± 2.8
Ad.36 hs + DMSO 48 hs 2.5 ± 1.8 50.2 ± 3.8 21.9 ± 3.0 28.9 ± 3.1
Ad. 36 hs + Flavopiridol 48 hs 9.9 ± 4.6 48.5 ± 4.0 23.4 ± 3.1 28.1 ± 3.1
Ad.72 hs 4.8 ± 0.6 12.9 ± 2.1 67.8 ± 6.8* 19.3 ± 1.9
Ad.72 hs + DMSO 48 hs 5.2 ± 0.9 16.1 ± 2.6 62.5 ± 4.3 21.4 ± 2.2
Ad. 72 hs + Flavopiridol 48 hs 60.1 ± 5.3** 51.8 ± 3.8 22.3 ± 3.0 25.9 ± 3.1
  1. *P < 0.01, **P < 0.01.